Prostate Cancer (Adenocarcinoma) clinical trials

Blood test to guide early stopping of prostate cancer therapy

This trial uses a blood test to measure tumor DNA and see if men with advanced prostate cancer can safely stop treatment with a drug called 177Lu-PSMA-617 earlier than usual, or switch to chemotherapy. It may help reduce side effects while still controlling the cancer.

Drug combination study for advanced prostate cancer

This study tests several new drug combinations for men with advanced prostate cancer that has spread and stopped responding to standard hormone treatments. It aims to find better ways to control the disease and improve outcomes.

Cryoablation and low-dose chemo for metastatic prostate cancer

This trial tests freezing prostate tumors (cryoablation) combined with a low-dose chemotherapy pill (metronomic cyclophosphamide) for men with metastatic prostate cancer. The goal is to see if this combination can slow the cancer's growth and improve outcomes.

Radioactive drugs before prostate surgery for high-risk prostate cancer

This trial compares two radioactive drugs (177Lu-PSMA-617 and 225Ac-PSMA-617) given before prostate removal surgery in men with high-risk prostate cancer that has not spread far. The goal is to see which drug is better at shrinking the tumor and reducing the chance of cancer coming back.

Study of I-DXd for metastatic prostate cancer

This study tests a new drug called Ifinatamab Deruxtecan (I-DXd) for people with metastatic prostate cancer that has stopped responding to hormone therapy. It may help by targeting and destroying cancer cells in a different way.

Enzalutamide plus relacorilant versus placebo for high-risk prostate cancer

This study tests whether adding relacorilant to enzalutamide (a hormone-blocking treatment) helps control high-risk localized prostate cancer better than enzalutamide plus a dummy pill. It may help prevent the cancer from growing or spreading by targeting a hormone pathway in addition to standard treatment.

Targeted therapy with or without hormone therapy for prostate cancer that has spread a little

This trial tests whether targeting the spots where cancer has returned with radiation or surgery, with or without hormone therapy, can help control prostate cancer that has come back in a few places after previous treatment.

MRI scans to guide biopsy for prostate cancer diagnosis

This study tests whether special MRI “risk maps” can help doctors better identify suspicious areas in the prostate during diagnosis. If you’re having an MRI followed by an MRI-guided biopsy, this may help improve how the biopsy targets areas of concern.

New drug combo for advanced prostate cancer

This study tests whether adding the investigational drug mevrometostat to the standard treatment enzalutamide works better than enzalutamide alone for men with prostate cancer that has spread to other parts of the body (metastatic castration-sensitive prostate cancer). You may benefit if you haven't yet received chemotherapy or similar strong treatments for this stage of cancer.

Blood test study for early cancer detection in patients

This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.

Adding chemo to hormone therapy for advanced prostate cancer

This trial is for men with metastatic prostate cancer that has already spread beyond the pelvis. It tests whether adding a chemotherapy drug (docetaxel) to the usual hormone therapy plus apalutamide can help control the cancer better than hormone therapy alone.

Study of AZD6621 for men with advanced prostate cancer

This study tests a new drug called AZD6621 for men with metastatic prostate cancer that no longer responds to standard hormone therapy. The goal is to see how safe it is and whether it can slow down the cancer.

Study of ASP5541 for metastatic prostate cancer

This study tests an experimental drug called ASP5541 for men with metastatic prostate cancer (either hormone-sensitive or castration-resistant). It aims to see if the drug can slow cancer growth and improve outcomes when added to standard hormone therapy.

JANX014 for Advanced Prostate Cancer

This study tests a new immunotherapy drug called JANX014 in men with advanced prostate cancer that has stopped responding to hormone treatments. The trial aims to find the right dose and see if this drug can help slow or stop cancer growth.

GDC-1261 Safety and Activity in Advanced Prostate Cancer

This early-stage trial tests a new drug called GDC-1261 in men with advanced prostate cancer that has spread or gotten worse despite previous treatment. The study will look at whether the drug is safe and whether it helps slow or shrink the cancer.

Hormone therapy dosing study for metastatic prostate cancer

This study tests different ways of giving hormone therapy to find the right dose for men with prostate cancer that has spread. It aims to help manage the disease while limiting side effects.

Study tests a new prostate cancer drug after prior hormone therapy

This Phase 1 study tests the safety, how the drug moves through the body, and whether it shows anti-cancer activity in men with advanced or metastatic prostate cancer. It is designed for people whose cancer has already been treated with certain hormone (androgen receptor) therapies.

Study of SHR-6914 for Prostate Cancer

This study tests a new drug called SHR-6914 in men with prostate cancer that has spread. The goal is to see if it is safe and helps shrink or control the cancer, and to learn how the body processes it.

Shorter radiation treatment for high-risk prostate cancer

This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.

Immunotherapy plus targeted radiation for advanced prostate cancer

This study combines two treatments: pembrolizumab, which helps your immune system fight cancer, and a targeted radioactive medicine (177Lu-PSMA-617) that seeks out and damages prostate cancer cells. It may help men whose prostate cancer has spread despite initial hormone therapy.

Prostate Cancer Registry and Research Study

This study collects medical information and tissue samples from men with prostate cancer to better understand the disease and improve future treatment. You'll provide consent and allow researchers to use your health data and biopsy samples for studies.

PET scan for high-risk prostate cancer before surgery

This trial uses a special PET scan to find prostate cancer cells before surgery. It may help doctors see where the cancer is located and if it has spread.

Multi-peptide Vaccination and Bispecific PSMAxCD3 Antibody Treatment in Patients With Prostate Cancer

Hormone Therapy and Radiation for Intermediate Risk Prostate Cancer

This study tests whether a combination of short-term hormone therapy (relugolix) and focused radiation (SBRT) can treat a certain type of prostate cancer that is considered favorable but has a higher genetic risk. It aims to find a less intense treatment that still works well.